

VictORION

A dynamic clinical trial program co-created with healthcare partners worldwide to generate evidence on the impact of cholesterol lowering with Leqvio® (inclisiran).



60,000
patients being enrolled



across
>50
countries



in
>30
trials

VictORION paves the way for inclisiran to transform the lives of millions of people affected by atherosclerotic cardiovascular disease (ASCVD).



Where we are now

Cardiovascular disease (CVD) is the #1 cause of death killing 18M people globally per year, more than cancer, respiratory diseases and diabetes combined¹



Statins alone are not enough for 4 in 5 ASCVD patients, putting them at risk of heart attack or stroke²⁻⁴



1 in 2 patients prescribed lipid-lowering therapy stop taking their medication after a year³⁻⁵



Up to 16% of health spending globally is used on managing CVD⁶

What we can improve

Expand use of innovative cholesterol-lowering treatment to improve health at a population level

Achieve and maintain guideline-recommended levels of Low Density Lipoprotein Cholesterol (LDL-C) through innovative cholesterol-lowering treatment on top of statins

Drive optimal LDL-C management with treatments that seamlessly integrate into routine care

Deliver substantial savings for healthcare systems through better cardiovascular health management

VictORION evidence generation

On-going clinical trials to demonstrate potential of inclisiran to improve outcomes for patients both before and after experiencing a CV event (primary and secondary prevention)^{*}

Clinical trials to show effective and sustained LDL-C lowering with inclisiran across different groups of people

Real-world evidence and community-level implementation to show potential for inclisiran to drive improved adherence with two doses a year^{**}

Cost-effectiveness analyses to show the economic benefits of using inclisiran

Key trials

ORION-4
VictORION-1-PREVENT
VictORION-2-PREVENT

ORION-8
ORION-9
ORION-10
ORION-11
ORION-18

VictORION-SPIRIT
VictORION-IMPLEMENT
V-REAL

VictORION-DIFFERENCE

Learn more about the full range of VictORION trials [here](#)

^{*} The effect of inclisiran on CVD mortality has not been established; ^{**} after an initial dose at three months.

References

1. Roth GA, Mensah GA, Johnson CO, et al. Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019. Update From the GBD 2019 Study [published correction appears in J Am Coll Cardiol. 2021 Apr 20;77(15):1958-1959]. J Am Coll Cardiol. 2020;76(25):3259-3272. doi:10.1016/j.jacc.2020.11.010. 2. Bruckert E, Perhofer KG, Gonzalez-Juansteyr JR, et al. Proportion of High-Risk Very High-Risk Patients in Europe with Low-Density Lipoprotein Cholesterol at Target According to European Guidelines: A Systematic Review. Adv Ther. 2020;37(1):724-735. 3. Lavinberg PJ, Lee A, Lee ZY, et al. Nonadherence to statins: individualized intervention strategies outside the pill box. Vasc Health Risk Manag. 2018;14(1):1-10. 4. Wang HJ, Young G, Zhao Y, et al. Prevalence of the American College of Cardiology/American Heart Association statin eligibility groups, statin use, and low-density lipoprotein cholesterol control in US adults using the National Health and Nutrition Examination Survey 2011-2012. J Clin Lipidol. 2018;10(5):1059-1065. 5. Turri A, Parodi J, Stone NJ. Statins and Nonadherence: Should We RE-LATE Better? J Cardiovasc Pharmacol Ther. 2015;20(3):447-458. doi:10.1177/107173428415517070. 6. Rittegaard T, Pelly A, Reddy CL, Barreiro E, Colombo F, Alun R. The State of Cardiovascular Disease in G20+ countries. Health Systems Innovation Lab, Harvard University, May 2022. DOI: 10.5411/0001/HISL/ovdg20